Eli Lilly and Co

Investors are pricing Merck (MRK) stock at 5.5 times sales, compared with 3.1 for the S&P 500. Shareholders paying that premium need to understand exactly what they hold, and the drugmaker's priorities have changed. During the fiscal Q4 2024 call in February 2025, executives noted that conditions for the GARDASIL vaccine in China remained challenging. By the August 4, 2026 call, management emphasized something else. So what does management talk up now.

Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the latest market and sector action, highlighting what the sell-off in CoreWeave (CRWV) and chip stocks means for the rest of the market.

Eli Lilly (NYSE: LLY) reported new clinical analyses showing its Omvoh therapy achieved corticosteroid free disease control at one year in ulcerative colitis and Crohn's disease. The data include patients with difficult to treat inflammatory bowel disease who had previously not responded to other biologic treatments. Eli Lilly also announced global oncology clinical trial alliances with Adlai Nortye and Prelude Therapeutics to expand its cancer pipeline research. Omvoh's one year...